Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products-stimulated chondrocytes

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Liu, Feng Cheng ^a,b   Hung, Li Feng ^c   Wu, Wan Lin ^c   Chang, Deh Ming ^a,b   Huang, Chuan Yueh ^c   Lai, Jenn Haung ^a,b   Ho, Ling Jun ^c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AGGRECAN; CHONDROPROTECTIVE AGENT; COLLAGENASE 3; CYCLOOXYGENASE 2; GELATIN; I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE 1; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; PROTEOGLYCAN; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL ISOLATION; CELL STIMULATION; CHONDROCYTE IMPLANTATION; CHONDROPROTECTION; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HISTOCHEMISTRY; NONHUMAN; OSTEOARTHRITIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; CARTILAGE; DRUG EFFECT; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; METABOLISM; SWINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CARTILAGE; CHONDROCYTES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNOPRECIPITATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STILBENES; SWINE; TRANSFECTION;

EID: 77956465167     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3127     Document Type: Article

References (49)

1. Herrero-Beaumont G, Roman-Blas JA, Castaneda S, Jimenez SA. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 2009, 39:71-80. 10.1016/j.semarthrit.2009.03.006, 19589561.
2. Abramson SB, Attur M. Developments in the scientific understanding of osteoarthritis. Arthritis Res Ther 2009, 11:227. 10.1186/ar2655, 2714096, 19519925.
3. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im HJ, Bursch LS, Yan SD. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis Rheum 2005, 52:2376-2385. 10.1002/art.21199, 1488730, 16052547.
4. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008, 10:209. 10.1186/ar2440, 2483460, 18598385.
5. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A, Bank RA, Mizrahi J, Schalkwijk CG, Thorpe SR, Baynes JW, Bijlsma JW, Lafeber FP, TeKoppele JM. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002, 46:114-123. 10.1002/1529-0131(200201)46:1<114::AID-ART10025>3.0.CO;2-P, 11822407.
6. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. Arthritis Rheum 2006, 54:2901-2911. 10.1002/art.22042, 16948116.
7. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010, 79:1379-1386. 10.1016/j.bcp.2010.01.013, 20096667.
8. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 2009, 10:530-546.
9. Penumathsa SV, Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 2009, 87:275-286. 10.1139/Y09-013, 19370081.
10. Mainardi T, Kapoor S, Bielory L. Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol 2009, 123:283-294. quiz 295-296, 10.1016/j.jaci.2008.12.023, 19203652.
11. Elmali N, Esenkaya I, Harma A, Ertem K, Turkoz Y, Mizrak B. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 2005, 54:158-162. 10.1007/s00011-004-1341-6, 15883738.
12. Shakibaei M, Csaki C, Nebrich S, Mobasheri A. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008, 76:1426-1439. 10.1016/j.bcp.2008.05.029, 18606398.
13. Dave M, Attur M, Palmer G, Al-Mussawir HE, Kennish L, Patel J, Abramson SB. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008, 58:2786-2797. 10.1002/art.23799, 18759268.
14. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 2008, 75:677-687. 10.1016/j.bcp.2007.09.014, 17959154.
15. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44:1237-1247. 10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F, 11407681.
16. Nah SS, Choi IY, Lee CK, Oh JS, Kim YG, Moon HB, Yoo B. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology (Oxford) 2008, 47:425-431. 10.1093/rheumatology/kem376, 18285354.
17. Huang CY, Hung LF, Liang CC, Ho LJ. COX-2 and iNOS are critical in advanced glycation end product-activated chondrocytes in vitro. Eur J Clin Invest 2009, 39:417-428. 10.1111/j.1365-2362.2009.02106.x, 19371268.
18. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997, 324:565-570. 1218467, 9182719.
19. Farboud B, Aotaki-Keen A, Miyata T, Hjelmeland LM, Handa JT. Development of a polyclonal antibody with broad epitope specificity for advanced glycation endproducts and localization of these epitopes in Bruch's membrane of the aging eye. Mol Vis 1999, 5:11.
20. Rasheed Z, Anbazhagan AN, Akhtar N, Ramamurthy S, Voss FR, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009, 11:R71. 10.1186/ar2700, 2714117, 19445683.
21. Lai JH, Ho LJ, Kwan CY, Chang DM, Lee TC. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology. Transplantation 1999, 68:1383-1392. 10.1097/00007890-199911150-00027, 10573080.
22. Ho LJ, Lin LC, Hung LF, Wang SJ, Lee CH, Chang DM, Lai JH, Tai TY. Retinoic acid blocks pro-inflammatory cytokine-induced matrix metalloproteinase production by down-regulating JNK-AP-1 signaling in human chondrocytes. Biochem Pharmacol 2005, 70:200-208. 10.1016/j.bcp.2005.04.039, 15946654.
23. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum 2007, 56:3326-3335. 10.1002/art.22879, 17907186.
24. Schmidt-Hansen B, Ornas D, Grigorian M, Klingelhofer J, Tulchinsky E, Lukanidin E, Ambartsumian N. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004, 23:5487-5495. 10.1038/sj.onc.1207720, 15122322.
25. Upton ML, Chen J, Setton LA. Region-specific constitutive gene expression in the adult porcine meniscus. J Orthop Res 2006, 24:1562-1570. 10.1002/jor.20146, 16732608.
26. Chou CH, Cheng WT, Kuo TF, Sun JS, Lin FH, Tsai JC. Fibrin glue mixed with gelatin/hyaluronic acid/chondroitin-6-sulfate tri-copolymer for articular cartilage tissue engineering: the results of real-time polymerase chain reaction. J Biomed Mater Res A 2007, 82:757-767.
27. van Lent PL, Grevers LC, Blom AB, Arntz OJ, van de Loo FA, van der Kraan P, Abdollahi-Roodsaz S, Srikrishna G, Freeze H, Sloetjes A, Nacken W, Vogl T, Roth J, van den Berg WB. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum 2008, 58:3776-3787. 10.1002/art.24074, 19035520.
28. Allport VC, Slater DM, Newton R, Bennett PR. NF-kappaB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol Hum Reprod 2000, 6:561-565. 10.1093/molehr/6.6.561, 10825375.
29. Cho MK, Suh SH, Kim SG. JunB/AP-1 and NF-kappa B-mediated induction of nitric oxide synthase by bovine type I collagen in serum-stimulated murine macrophages. Nitric Oxide 2002, 6:319-332. 10.1006/niox.2001.0415, 12009850.
30. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001, 29:4361-4372. 10.1093/nar/29.21.4361, 60184, 11691923.
31. Verzijl N, DeGroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, Bayliss MT, Bijlsma JW, Lafeber FP, Tekoppele JM. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000, 350:381-387. 10.1042/0264-6021:3500381, 1221264, 10947951.
32. DeGroot J, Verzijl N, Bank RA, Lafeber FP, Bijlsma JW, TeKoppele JM. Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation. Arthritis Rheum 1999, 42:1003-1009. 10.1002/1529-0131(199905)42:5<1003::AID-ANR20>3.0.CO;2-K, 10323457.
33. DeGroot J, Verzijl N, Wenting-van Wijk MJ, Jacobs KM, Van El B, Van Roermund PM, Bank RA, Bijlsma JW, TeKoppele JM, Lafeber FP. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum 2004, 50:1207-1215. 10.1002/art.20170, 15077303.
34. Handl M, Filova E, Kubala M, Lansky Z, Kolacna L, Vorlicek J, Trc T, Pach M, Amler E. Fluorescent advanced glycation end products in the detection of factual stages of cartilage degeneration. Physiol Res 2007, 56:235-242.
35. Amin AR, Attur M, Abramson SB. Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 1999, 11:202-209. 10.1097/00002281-199905000-00009, 10328580.
36. Abramson SB, Attur M, Amin AR, Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 2001, 3:535-541. 10.1007/s11926-001-0069-3, 11709117.
37. Pelletier JP, Jovanovic D, Fernandes JC, Manning P, Connor JR, Currie MG, Di Battista JA, Martel-Pelletier J. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998, 41:1275-1286. 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T, 9663486.
38. Pelletier JP, Jovanovic DV, Lascau-Coman V, Fernandes JC, Manning PT, Connor JR, Currie MG, Martel-Pelletier J. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum 2000, 43:1290-1299. 10.1002/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R, 10857787.
39. Pelletier JP, Fernandes JC, Jovanovic DV, Reboul P, Martel-Pelletier J. Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. J Rheumatol 2001, 28:2509-2519.
40. Sadowski T, Steinmeyer J. Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 2001, 9:407-415. 10.1053/joca.2000.0406, 11467888.
41. Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 2009, 8:480-499. 10.1038/nrd2829, 19483709.
42. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996, 97:761-768. 10.1172/JCI118475, 507114, 8609233.
43. Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P, DeGennaro LJ. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001, 107:35-44. 10.1172/JCI10564, 198546, 11134178.
44. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543. 10.2741/1817, 16146751.
45. Miwa HE, Gerken TA, Hering TM. Effects of covalently attached chondroitin sulfate on aggrecan cleavage by ADAMTS-4 and MMP-13. Matrix Biol 2006, 25:534-545. 10.1016/j.matbio.2006.07.004, 16945513.
46. Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002, 106:1652-1658. 10.1161/01.CIR.0000029925.18593.5C, 12270858.
47. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP, Bertelli A. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 1998, 24:51-55.
48. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998, 24:133-138.
49. Tan Y, Lim LH. trans-Resveratrol, an extract of red wine, inhibits human eosinophil activation and degranulation. Br J Pharmacol 2008, 155:995-1004. 10.1038/bjp.2008.330, 2597253, 18776917.